BioDuro Opens State-of-the-Art Discovery Lab in Shanghai
News May 17, 2013
BioDuro announced it has opened a new state-of-the-art laboratory in Shanghai, strengthening its ability to provide biopharmaceutical clients an extensive range of customized drug discovery services in Asia Pacific. The new lab also enables the company to better support the business needs of its clients by increasing efficiency during discovery and development, and providing greater consistency among the stages of development. In addition, the location of the lab in the Waigaoqiao Free Trade Zone and its proximity to local and multinational pharmaceutical and biotechnology companies in Shanghai will foster their working relationships with BioDuro.
The 72,000-square-foot lab, accompanied by 20,000 square feet of office space, offers integrated drug metabolism and pharmacokinetic (DMPK), bioanalytical, chemistry, discovery biology and oncology pharmacology services. And, because BioDuro is part of the PPD organization, clients also are able to take advantage of a complete menu of clinical research services, as well as an extensive library of assays for testing.
“As a fully integrated life science research service provider, BioDuro has an experienced team of researchers and scientists with expertise in a wide range of drug discovery services,” said Jasmine Cui, Ph.D., general manager and chief scientific officer of BioDuro. “This new lab will allow us to meet the business needs of our clients more effectively by streamlining the discovery and development process, and continuing to enhance continuity and smooth transitions throughout the stages of development. For example, after a compound goes into Phase 0, the PPD organization can offer full clinical research services to develop the compound through post approval.”
BioDuro also has a state-of-the-art, 110,000-square-foot laboratory in Beijing. Through the two operations, BioDuro provides fully integrated, comprehensive drug discovery services covering development from target identification to preclinical/Phase 0.
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
BioAscent Announces New CEO and Plans to Expand Discovery Services OfferingNews
BioAscent Discovery Limited appoints new CEO, Paul Smith in preparation for the expansion of companies discovery services.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018